Quince Therapeutics, Inc. (IRLA): Operating Cash Flow
-$41.42M
Year ended 2025-12-31
-$46.92M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$41.42M | n/m | 2026-04-10, From 2025-01-01 |
| 2024-12-31 | -$31.90M | n/m | 2026-04-10, From 2024-01-01 |
| 2023-12-31 | -$18.29M | n/m | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | -$44.04M | n/m | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | -$62.93M | n/m | 2023-03-15, From 2021-01-01 |
| 2020-12-31 | -$50.82M | n/m | 2022-03-01, From 2020-01-01 |
| 2019-12-31 | -$33.28M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | -$11.70M | n/a | 2021-03-01, From 2018-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Quince Therapeutics, Inc. (IRLA) | 2025-12-31 | -$41.42M | n/m |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | -$61.99M | n/m |
| LeonaBio, Inc. (LONA) | 2025-12-31 | -$45.73M | n/m |
| Surrozen, Inc. (SRZN) | 2025-12-31 | -$30.24M | n/m |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | -$82.50M | n/m |
| Anavex Life Sciences Corp. (AVXL) | 2025-09-30 | -$39.04M | n/m |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | -$11.99M | n/m |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | -$20.38M | n/m |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | -$18.92M | n/m |
Compare IRLA, ATYR, LONA, SRZN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗